CAS 98116-53-1
:Sulukast
Description:
Sulukast, with the CAS number 98116-53-1, is a chemical compound that belongs to the class of leukotriene receptor antagonists. It is primarily used in the treatment of asthma and allergic rhinitis by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and mucus production. Sulukast is characterized by its ability to reduce airway inflammation and improve respiratory function. The compound typically exhibits good oral bioavailability and is metabolized in the liver, with a favorable safety profile. Its pharmacological effects are achieved through selective binding to the cysteinyl leukotriene receptor, thereby blocking the action of leukotrienes such as LTC4, LTD4, and LTE4. This mechanism helps alleviate symptoms associated with asthma and allergic conditions. As with any medication, potential side effects may include gastrointestinal disturbances, headache, and fatigue, although these are generally mild. Overall, Sulukast represents a valuable therapeutic option in managing respiratory conditions linked to leukotriene activity.
Formula:C25H36N4O3S
InChI:InChI=1/C25H36N4O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16-22(33-18-17-23(30)31)24(32)20-14-13-15-21(19-20)25-26-28-29-27-25/h10-16,19,22,24,32H,2-9,17-18H2,1H3,(H,30,31)(H,26,27,28,29)/b11-10-,16-12+/t22-,24+/m1/s1
Synonyms:- Sulukast [USAN:INN]
- Ly 170680
- 3-(((1R,2E,4Z)-1-((alphaS)-alpha-Hydroxy-m-1H-tetrazol-5-ylbenzyl)-2,4-tetradecadienyl)thio)propionic acid
- Propanoic acid, 3-((1-(hydroxy(3-(1H-tetrazol-5-yl)phenyl)methyl)-2,4-tetradecadienyl)thio)-, (R-(R*,S*-(E,Z)))-
- Sulukastum
- Sulukastum [INN-Latin]
- Unii-M652A5186T
- 3-{[(1R,2E,4Z)-1-{(S)-hydroxy[3-(2H-tetrazol-5-yl)phenyl]methyl}tetradeca-2,4-dien-1-yl]sulfanyl}propanoic acid
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Sulukast
CAS:<p>Sulukast is a leukotriene receptor antagonist that blocks leukotriene-induced bronchoconstriction. It is used in the treatment of asthma and chronic obstructive pulmonary disease. Sulukast binds to two types of receptors, the cysteinyl leukotriene receptor 1 (CysLT1) and the cysteinyl leukotriene receptor 2 (CysLT2). The binding activates adenyl cyclase, which leads to increased levels of cyclic AMP. This increase in cyclic AMP causes an increase in calcium influx into cells and activation of protein kinase A, resulting in phosphorylation and deactivation of CysLT1s. Sulukast also inhibits the binding of peptides to receptors on cells, which may be useful for research purposes.<br> *Sulukast is a high-purity ligand with a purity greater than 99%. It has a molecular weight</p>Formula:C25H36N4O3SPurity:Min. 95%Molecular weight:472.60 g/mol
